Table IV.
European Organization for Research and Treatment of Cancer QLQ-C30 and BN20 scores according to time from initial treatment, age, KPS, history of recurrence, chemotherapy and leukoencephalopathy in patients with primary central nervous system lymphoma.
| Time since diagnosis | Age at QOL survey | KPS at QOL survey | History of recurrence | Chemotherapy | Leukoencephalopathy | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | <5 years | ≥5 years | P-value (t-test) | <65 years | ≥65 years | P-value (t-test) | <80 | ≥80 | P-value (t-test) | + | − | P-value (t-test) | <8 cycles | ≥8 cycles | P-value (t-test) | Grade 1 | Grade 2–3 | P-value |
| Number of cases | 27 | 10 | 17 | 20 | 16 | 21 | 16 | 21 | 27 | 10 | 7 | 30 | ||||||
| Gender | ||||||||||||||||||
| Male | 19 | 6 | 13 | 12 | 9 | 16 | 12 | 13 | 16 | 9 | 6 | 19 | ||||||
| Female | 8 | 4 | 4 | 8 | 7 | 5 | 4 | 8 | 11 | 1 | 1 | 11 | ||||||
| Age at QOL survey, yrs | ||||||||||||||||||
| Median | 67 | 58 | 57 | 69 | 69 | 60 | 66 | 63 | 65 | 66 | 59 | 67.5 | ||||||
| Range | 39–81 | 43–79 | 39–63 | 65–81 | 48–81 | 39–79 | 48–81 | 39–79 | 39–79 | 48–81 | 39–65 | 48–81 | ||||||
| QLQ C-30 funct. | ||||||||||||||||||
| 1) Global health | 61.1±25.0 | 67.5±29.8 | 0.5 | 68.6±30.3 | 57.9±21.5 | 0.2 | 53.6±25.1 | 69.8±25.2 | 0.06 | 66.7±25.5 | 59.9±26.8 | 0.4 | 61.7±26.6 | 65.8±25.9 | 0.7 | 73.8±31.7 | 60.3±24.5 | 0.2 |
| 2) Physical funct. | 66.2±33.0 | 71.3±35.4 | 0.7 | 85.1±19.4 | 52.7±35.6 | 0.002 | 39.2±31.1 | 89.2±11.2 | <0.0001 | 56.3±38.6 | 76.2±26.2 | 0.07 | 71.9±32.3 | 56.0±34.6 | 0.2 | 96.2±7.6 | 60.9±33.4 | 0.009 |
| 3) Role funct. | 64.8±34.1 | 76.7±35.3 | 0.4 | 84.3±24.6 | 54.2±35.8 | 0.006 | 44.8±34.8 | 85.7±21.3 | <0.0001 | 59.4±39.9 | 74.6±28.7 | 0.2 | 71.6±33.6 | 58.3±36.2 | 0.3 | 92.9±18.9 | 62.2±34.7 | 0.03 |
| 4) Emotional funct. | 82.4±19.0 | 84.2±14.9 | 0.8 | 86.3±19.8 | 80.0±15.9 | 0.3 | 82.8±15.7 | 82.9±19.6 | 0.98 | 83.9±13.4 | 82.1±20.8 | 0.8 | 82.7±19.6 | 83.3±12.4 | 0.9 | 97.6±4.1 | 79.4±18.0 | 0.01 |
| 5) Cognitive funct. | 64.8±27.9 | 83.3±20.8 | 0.06 | 84.3±21.6 | 57.5±25.6 | 0.002 | 57.3±30.4 | 79.4±20.3 | 0.01 | 66.7±25.1 | 72.2±29.0 | 0.5 | 69.8±30.3 | 70.0±17.2 | 0.98 | 95.2±8.1 | 63.9±26.7 | 0.004 |
| 6) Social funct. | 68.5±34.1 | 81.7±26.6 | 0.3 | 84.3±23.9 | 61.7±35.5 | 0.03 | 52.1±34.9 | 87.3±20.3 | 0.0005 | 65.6±28.8 | 77.0±34.8 | 0.3 | 74.1±35.3 | 66.7±23.6 | 0.5 | 92.9±13.1 | 67.2±33.8 | 0.06 |
| QLQ C-30 symptoms | ||||||||||||||||||
| 7) Fatigue | 35.0±27.9 | 18.9±20.3 | 0.1 | 20.3±22.6 | 39.4±27.3 | 0.03 | 45.1±27.1 | 19.6±21.1 | 0.003 | 32.6±25.8 | 29.1±28.0 | 0.7 | 30.0±29.5 | 32.2±18.5 | 0.8 | 3.2±5.4 | 37.0±25.7 | 0.002 |
| 8) N/V | 3.7±13.3 | 0.0±0.0 | 0.4 | 4.9±16.4 | 0.8±3.7 | 0.3 | 1.0±4.2 | 4.0±14.8 | 0.4 | 5.2±16.9 | 0.8±3.6 | 0.3 | 1.2±4.4 | 6.7±21.1 | 0.2 | 2.4±6.3 | 2.8±12.4 | 0.9 |
| 9) Pain | 11.1±14.6 | 5.0±11.2 | 0.2 | 8.8±15.7 | 10.0±12.6 | 0.8 | 11.5±13.2 | 7.9±14.5 | 0.5 | 7.3±12.1 | 11.1±15.2 | 0.4 | 9.9±14.1 | 8.3±14.2 | 0.8 | 2.4±6.3 | 11.1±14.7 | 0.1 |
| 10) Dyspnea | 11.1±24.5 | 3.3±10.5 | 0.3 | 7.8±14.6 | 10.0±26.7 | 0.8 | 14.6±29.7 | 4.8±12.0 | 0.2 | 10.4±26.4 | 7.9±18.0 | 0.7 | 9.9±24.1 | 6.7±14.1 | 0.7 | 4.8±12.6 | 10.0±23.4 | 0.6 |
| 11) Insomnia | 21.0±29.5 | 13.3±23.3 | 0.5 | 19.6±26.5 | 18.3±29.6 | 0.9 | 20.8±31.9 | 17.5±25.0 | 0.7 | 16.7±24.3 | 20.6±30.7 | 0.7 | 18.5±29.7 | 20.0±23.3 | 0.9 | 4.8±12.6 | 22.2±29.5 | 0.1 |
| 12) Appetite loss | 8.6±14.9 | 3.3±10.5 | 0.3 | 3.9±11.1 | 10.0±15.7 | 0.2 | 10.4±16.0 | 4.8±12.0 | 0.2 | 8.3±14.9 | 6.3±13.4 | 0.7 | 6.2±13.2 | 10.0±16.1 | 0.5 | 0.0±0.0 | 8.9±15.0 | 0.1 |
| 13) Constipation | 21.0±28.0 | 16.7±23.6 | 0.7 | 17.6±26.7 | 21.7±27.1 | 0.7 | 22.9±29.1 | 17.5±25.0 | 0.5 | 18.8±24.2 | 20.6±28.8 | 0.8 | 19.8±28.1 | 20.0±23.3 | 0.98 | 0.0±0.0 | 24.4±27.6 | 0.03 |
| 14) Diarrhea | 3.7±10.7 | 3.3±10.5 | 0.9 | 3.9±11.1 | 3.3±10.3 | 0.9 | 4.2±11.4 | 3.2±10.0 | 0.8 | 4.2±11.4 | 3.2±10.0 | 0.8 | 2.5±8.9 | 6.7±14.1 | 0.3 | 0.0±0.0 | 4.4±11.5 | 0.3 |
| 15) Financial issues | 17.3±23.3 | 10.0±16.1 | 0.4 | 15.7±26.7 | 15.0±17.0 | 0.9 | 20.8±16.7 | 11.1±24.3 | 0.2 | 20.8±16.7 | 11.1±24.3 | 0.2 | 12.3±22.9 | 23.3±16.1 | 0.2 | 0.0±0.0 | 18.9±22.6 | 0.04 |
| BN20 | ||||||||||||||||||
| 1) Future uncertainty | 25.3±25.1 | 12.5±14.3 | 0.1 | 17.2±22.5 | 25.8±23.6 | 0.3 | 26.6±25.5 | 18.3±21.2 | 0.3 | 24.5±23.1 | 19.8±23.6 | 0.6 | 21.0±23.7 | 24.2±22.7 | 0.7 | 6.0±7.9 | 25.6±24.1 | 0.04 |
| 2) Visual disorder | 16.0±21.4 | 6.7±9.4 | 0.2 | 5.9±16.7 | 20.0±19.3 | 0.02 | 20.8±19.8 | 7.9±17.3 | 0.04 | 12.5±17.2 | 14.3±21.1 | 0.8 | 14.0±19.9 | 12.2±18.5 | 0.8 | 0.0±0.0 | 16.7±20.2 | 0.04 |
| 3) Motor dysfunction | 21.8±22.7 | 16.7±21.1 | 0.5 | 15.7±22.6 | 24.4±21.5 | 0.2 | 29.2±21.4 | 13.8±20.8 | 0.03 | 20.8±24.3 | 20.1±21.0 | 0.9 | 21.8±23.0 | 16.7±20.5 | 0.5 | 9.5±17.5 | 23.0±22.6 | 0.2 |
| 4) Comm. deficit | 28.0±29.3 | 18.9±22.9 | 0.4 | 16.3±22.9 | 33.3±29.5 | 0.06 | 43.8±27.7 | 11.6±18.4 | 0.0002 | 30.6±30.8 | 21.7±25.2 | 0.3 | 21.0±25.1 | 37.8±31.9 | 0.1 | 12.7±25.2 | 28.5±27.8 | 0.2 |
| 5) Headache | 9.9±15.5 | 16.7±17.6 | 0.3 | 11.8±16.4 | 11.7±16.3 | 0.99 | 12.5±16.7 | 11.1±16.1 | 0.8 | 8.3±14.9 | 14.3±16.9 | 0.3 | 12.3±16.4 | 10.0±16.1 | 0.7 | 9.5±16.3 | 12.2±16.3 | 0.7 |
| 6) Seizure | 3.7±10.7 | 6.7±21.1 | 0.6 | 5.9±17.6 | 3.3±10.3 | 0.6 | 6.3±18.1 | 3.2±10.0 | 0.5 | 4.2±11.4 | 4.8±15.9 | 0.9 | 3.7±14.1 | 6.7±14.1 | 0.6 | 9.5±25.2 | 3.3±10.2 | 0.3 |
| 7) Drowsiness | 40.7±26.7 | 43.3±35.3 | 0.8 | 25.5±18.7 | 55.0±29.2 | 0.001 | 60.4±30.4 | 27.0±17.1 | 0.0001 | 52.1±29.7 | 33.3±25.8 | 0.048 | 35.8±27.6 | 56.7±27.4 | 0.049 | 28.6±23.0 | 44.4±29.5 | 0.2 |
| 8) Itchy skin | 21.0±21.0 | 26.7±21.1 | 0.5 | 21.6±20.2 | 23.3±21.9 | 0.8 | 25.0±25.8 | 20.6±16.6 | 0.5 | 16.7±21.1 | 27.0±20.1 | 0.1 | 27.2±20.7 | 10.0±16.1 | 0.02 | 28.6±23.0 | 21.1±20.5 | 0.4 |
| 9) Hair loss | 12.3±22.9 | 10.0±22.5 | 0.8 | 7.8±18.7 | 15.0±25.3 | 0.3 | 14.6±21.0 | 9.5±23.9 | 0.5 | 16.7±27.2 | 7.9±18.0 | 0.2 | 11.1±24.5 | 13.3±17.2 | 0.8 | 23.8±41.8 | 8.9±15.0 | 0.1 |
| 10) Leg weakness | 40.7±32.5 | 23.3±22.5 | 0.1 | 23.5±22.9 | 46.7±33.2 | 0.02 | 52.1±32.1 | 23.8±23.9 | 0.004 | 35.4±33.3 | 36.5±29.6 | 0.9 | 37.0±31.1 | 33.3±31.4 | 0.8 | 14.3±26.2 | 41.1±29.9 | 0.04 |
| 11) Bladder control | 22.2±27.7 | 26.7±41.0 | 0.7 | 17.6±29.1 | 28.3±32.9 | 0.3 | 39.6±37.0 | 11.1±19.2 | 0.005 | 22.9±29.1 | 23.8±33.6 | 0.9 | 24.7±34.1 | 20.0±23.3 | 0.7 | 19.0±37.8 | 24.4±30.2 | 0.7 |
Values are expressed as the mean ± standard deviation. QOL, quality of life; KPS, Karnofsky performance status; funct., functioning; N/V, nausea and vomiting; comm., communication.